{'52WeekChange': -0.27385372,
 'SandP52WeekChange': 0.0644362,
 'address1': '400 Alexander Park',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 30,
 'askSize': 900,
 'averageDailyVolume10Day': 91675,
 'averageVolume': 188376,
 'averageVolume10days': 91675,
 'beta': 1.705467,
 'beta3Year': None,
 'bid': 20.88,
 'bidSize': 2900,
 'bookValue': 7.093,
 'category': None,
 'circulatingSupply': None,
 'city': 'Princeton',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 24.14,
 'dayLow': 23.41,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.361,
 'enterpriseToRevenue': 22164.914,
 'enterpriseValue': 398968480,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 25.87,
 'fiftyTwoWeekHigh': 37.075,
 'fiftyTwoWeekLow': 13.118,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 18675351,
 'forwardEps': -4.56,
 'forwardPE': -5.1403513,
 'fromCurrency': None,
 'fullTimeEmployees': 174,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.124189995,
 'heldPercentInstitutions': 0.81281996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/urogen.com',
 'longBusinessSummary': 'UroGen Pharma Ltd., a clinical stage '
                        'biopharmaceutical company, focuses on developing '
                        'solutions for specialty cancers and urologic '
                        "diseases. The company's lead product candidates are "
                        'UGN-101 and UGN-102, which are designed to ablate '
                        'tumors by non-surgical means and to treat several '
                        'forms of non-muscle invasive urothelial cancer that '
                        'include low-grade upper tract urothelial carcinoma '
                        'and low-grade non-muscle invasive bladder cancer. It '
                        'is also developing UGN-201, a proprietary '
                        'immunotherapy product candidate for the treatment of '
                        'high-grade non-muscle invasive bladder cancer. The '
                        'company has a license agreement with Allergan '
                        'Pharmaceuticals International Limited for developing '
                        'and commercializing pharmaceutical products that '
                        'contain RTGel and clostridial toxins; and Agenus Inc. '
                        'to develop, make, use, sell, import, and '
                        'commercialize products of Agenus for the treatment of '
                        'cancers of the urinary tract via intravesical '
                        'delivery. UroGen Pharma Ltd. was founded in 2004 and '
                        'is based in Princeton, New Jersey.',
 'longName': 'UroGen Pharma Ltd.',
 'market': 'us_market',
 'marketCap': 514158752,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_240702165',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -121495000,
 'nextFiscalYearEnd': 1640908800,
 'open': 24.14,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646 768 9780',
 'previousClose': 24.12,
 'priceHint': 2,
 'priceToBook': 3.3046668,
 'priceToSalesTrailing12Months': 28564.375,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 24.14,
 'regularMarketDayLow': 23.41,
 'regularMarketOpen': 24.14,
 'regularMarketPreviousClose': 24.12,
 'regularMarketPrice': 24.14,
 'regularMarketVolume': 96193,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 21935100,
 'sharesPercentSharesOut': 0.1291,
 'sharesShort': 2832314,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2768256,
 'shortName': 'UroGen Pharma Ltd.',
 'shortPercentOfFloat': 0.16059999,
 'shortRatio': 16.01,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'URGN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -5.79,
 'twoHundredDayAverage': 25.418669,
 'volume': 96193,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.urogen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '08540'}